Part 2 -Patient Empowerment: Is it a no-brainer?

P4A’s 2 part -Patient Empowerment podcast series has been released. Our incredible panel of experts Laurence Woollard, Neil Bertelsen & Sophie Schmitz are back with us to carry on the discussion in part 2 on true patient empowerment and really looking at the WHY’s! Why should drug manufacturers involve & listen to and involve the patients. What are the implications, if any, for drug manufacturers who do not include the patient voice. How can we bring all stakeholders together to work completely new approaches to medicine approval and patient access. Lastly, we will look at initiatives or services our panel are offering to try to bridge the gaps and barriers for sustainable patient access.

P4A’s’’Let’s talk rare’’ monthly podcasts are available wherever you listen to your podcasts. If you are a drug manufacturer and you haven’t yet listened, this needs to be at the top of your to do list!

If you missed out on part 1 – listen here: https://spotifyanchor-web.app.link/e/hOBI3UqkPtb

Hosts: Georgie Rack (G-Rack)  & Owen Bryant (OB1)

Produced by: Operations Team

Links:

P4A’s PCAC: https://partners4access.com/services/pc-council/

Part One: Patient Empowerment: https://spotifyanchor-web.app.link/e/hOBI3UqkPtb

ABPI article in recognition of Rare Disease Day 2022 – “Moving      beyond box-ticking and lip-service – why patient involvement matters in a      new era of ATMPs for rare diseases”

James Lind Alliance Priority Setting Partnership –

“Setting       priorities for bleeding disorders – Final report” (2018)

“More than a Top 10: How James Lind Alliance Priority Setting Partnerships transform research, people and organisations” (2019)